AVBP Stock Discussion
ArriVent BioPharma, Inc. Description
ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor that is in phase 3 clinical trial for the treatment of NSCLC patients; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Solid Tumors Cancer Treatment Non Small Cell Lung Cancer Antineoplastic Drugs Lung Cancer Orphan Drug Protein Kinase Inhibitor Tyrosine Kinase Cancer Therapies NSCLC Bemcentinib
Recent Comments
- TraderMike on IZM
- SuccessfulGerbil321 on IZM
- TraderMike on IZM
- TraderMike on Today's Outage
- Crunching_The_Market on Today's Outage
From the Blog
Popular Now
Featured Articles